SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dale Meunier who wrote (13544)8/18/1998 2:48:00 AM
From: VLAD  Read Replies (2) of 23519
 
Dale,

Perhaps we are being overly cautious or even paranoid.

Another way of interpreting these 2 sentences may be as follows:

"The company has recently experienced manufacturing difficulties that have resulted in production and shipment delays and higher costs"

Possibly this is referring to the problems experienced back when the Company was moving equipment from the old to the new plant. Or this could be something which occurred in Q2 and effected earnings in Q2. This may also explain why countries such as Sweden and Switzerland just launched MUSE a week ago when they had approval months ago.

"In turn, revenues from the sale of MUSE will be delayed, which will have a material adverse effect on the Company's business, financial condition and results of operations."

This may be referring to what has already happened in Q2. If it is referring to Q3 perhaps the affect has already been factored in the earnings estimates and this is why Zacks dropped estimates a week ago from .09 to .04?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News